NCT01606735View on ClinicalTrials.gov

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Inflammation Associated With Cataract Surgery
Interventions
DRUG

IBI-10090

dexamethasone

Trial Locations (2)

92545

Inland Eye Specialists, Hemet

92591

California Eye Professionals, Temecula

Sponsors
All Listed Sponsors
lead

ICON Bioscience Inc

INDUSTRY